NTRR Seeks Out Alternative Cannabinoid Treatments for Pain Management
SARASOTA, Fla.--(BUSINESS WIRE)-- As part of its initiative to market and develop healthier, more effective alternatives to smoking for medical marijuana patients, Neutra Corp. (OTCBB: NTRR) is currently exploring cutting-edge, alternative cannabinoid treatments for those who need it most: patients who suffer from chronic pain.
Recent studies have suggested that cannabis-derived treatments can be safe and effective in the treatment of neuropathic pain, rheumatoid arthritis and cancer pain—three notoriously difficult ailments to alleviate. Additionally, injections of synthetic cannabinoids have shown great promise in enhancing morphine's antinociceptive effect while preventing the buildup of tolerance to the drug in patients.
With pain affecting 1.5 billion people worldwide, drugs and analgesics to treat it comprise one of the major segments of the central nervous system (CNS) therapies market. NTRR believes that cannabinoid treatments could hold the key to unlocking a whole new era of pain management, helping the company to break into the $52 billion pain management market. NTRR is seeking out potential partners who are developing breakthrough delivery systems capable of helping patients cope with chronic pain in new, more effective ways.
The company is dedicated to commercializing innovative, all-natural products to compete in the fast-growing medical marijuana sector alongside Cannabis Science Inc. (PINK: CBIS), Medical Marijuana Inc. (PINK: MJNA), HEMP Inc. (PINK: HEMP) and Growlife Inc. (PINK: PHOT).
For more information on NTRR's initiatives, please visit www.neutracorp.com/investors.html.
Follow NTRR on Twitter at www.twitter.com/neutracorp.
About Neutra Corp.
Neutra Corp. (www.neutracorp.com) is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products and services as well as protective, anti-microbial coatings for indoor and outdoor surfaces. For investing information and performance data, please visit www.neutracorp.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Cindy Morrissey, 713-821-1486
President and CEO
KEYWORDS: United States North America Florida
The article NTRR Seeks Out Alternative Cannabinoid Treatments for Pain Management originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.